Clinical Trial Update: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial protocol update for NRSTS2021, a Phase 1/2 study evaluating maintenance pazopanib, limited-margin radiation therapy, and selinexor in n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiomatoid Fibrous Histiocytoma
• Angiosarcoma
• Atypical Fibroxanthoma
• Fibrosarcoma
• Liposarcoma
• Myoepithelioma
• Myxofibrosarcoma
• Non-rhabdomyosarcoma Soft Tissue Sarcoma

Drugs mentioned

• Pazopanib (Votrient) (Pazopanib)
• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Adipocytic Neoplasm, Liposarcoma | Phase 1, Phase 2 | Status: RECRUITING